Sanofi Other Operating Income or Expenses 2010-2024 | SNY
Sanofi annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Sanofi other operating income or expenses for the quarter ending September 30, 2024 were $-1.079B, a 72.07% increase year-over-year.
- Sanofi other operating income or expenses for the twelve months ending September 30, 2024 were $-3.931B, a 125.95% increase year-over-year.
- Sanofi annual other operating income or expenses for 2023 were $-2.448B, a 149.32% increase from 2022.
- Sanofi annual other operating income or expenses for 2022 were $-0.982B, a 12.73% decline from 2021.
- Sanofi annual other operating income or expenses for 2021 were $-1.125B, a 114.49% decline from 2020.
Sanofi Annual Other Operating Income or Expenses
(Millions of US $) |
| 2023 |
$-2,448 |
| 2022 |
$-982 |
| 2021 |
$-1,125 |
| 2020 |
$7,766 |
| 2019 |
$-62 |
| 2018 |
$517 |
| 2017 |
$-238 |
| 2016 |
$93 |
| 2015 |
$-231 |
| 2014 |
$218 |
| 2013 |
$596 |
| 2012 |
$139 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Sanofi Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-09-30 |
$-1,079 |
| 2024-06-30 |
$-1,286 |
| 2024-03-31 |
$-696 |
| 2023-12-31 |
$-871 |
| 2023-09-30 |
$-627 |
| 2023-06-30 |
$-530 |
| 2023-03-31 |
$-421 |
| 2022-12-31 |
$-162 |
| 2022-09-30 |
$186 |
| 2022-06-30 |
$-689 |
| 2022-03-31 |
$-318 |
| 2021-09-30 |
$-346 |
| 2021-06-30 |
|
| 2021-03-31 |
$-122 |
| 2020-09-30 |
$-213 |
| 2020-03-31 |
$-140 |
| 2019-09-30 |
$-196 |
| 2019-03-31 |
$-116 |
| 2018-03-31 |
$-98 |
| 2017-12-31 |
$-188 |
| 2017-09-30 |
$-154 |
| 2017-06-30 |
$67 |
| 2017-03-31 |
$36 |
| 2016-12-31 |
$149 |
| 2016-09-30 |
$-133 |
| 2016-06-30 |
$-26 |
| 2016-03-31 |
$103 |
| 2015-09-30 |
$-151 |
| 2015-06-30 |
$-22 |
| 2014-06-30 |
$74 |
| 2013-06-30 |
$183 |
| 2012-06-30 |
$-195 |
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
